Last reviewed · How we verify
Live Attenuated Varicella Vaccine
Live Attenuated Varicella Vaccine, marketed by Changchun Changsheng Life Science and Technology Co., Ltd., holds a position in the varicella vaccination market. The key composition patent is set to expire in 2028, which may currently serve as a barrier to entry for competitors. Upon patent expiry, the company faces the risk of increased competition and potential revenue erosion.
At a glance
| Generic name | Live Attenuated Varicella Vaccine |
|---|---|
| Sponsor | Changchun Changsheng Life Science and Technology Co., Ltd. |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Second Dose of Varicella Vaccine in Healthy Children (PHASE3)
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years (PHASE3)
- Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine (PHASE1, PHASE2)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept (PHASE2)
- Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (PHASE2)
- Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion) (PHASE4)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: